Research Square·8 OctA Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB)Preprint: trial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecImpact of AD Co‐Pathology on Response to Neflamapimod (p38α Kinase Inhibitor) in Patients with Dementia with Lewy BodiesTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecEffects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co‐PathologyTrial in peopleInterventionsPaper